Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities-Reference-Cited by-同舟云学术

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities

Published:2017-06-08 Issue:10 Volume:11 Page:1238-1246
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Coutzac Clélia¹²,Adam Julien³⁴,Soularue Emilie¹²⁵,Collins Michael²⁵,Racine Antoine²⁵,Mussini Charlotte⁶,Boselli Lisa¹,Kamsukom Nyam⁷,Mateus Christine⁷,Charrier Mélinda¹²,Cassard Lydie¹,Planchard David⁸,Ribrag Vincent⁹,Fizazi Karim²¹⁰,Loriot Yohann¹⁰,Lepage Patricia¹¹,Scoazec Jean-Yves²³⁴,Robert Caroline²⁷,Carbonnel Franck²⁵,Chaput Nathalie¹¹²

Affiliation:

1. Gustave Roussy, Laboratory d’Immunomonitoring en Oncologie, CNRS-UMS 3655 and INSERM-US23, Villejuif F-94805, France

2. University Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, F-94276, France

3. Gustave Roussy, Department of Pathology and Laboratory Medicine [BIOpath], Villejuif F-94805, France

4. Gustave Roussy, AMMICa, CNRS-UMS 3655 and INSERM-US23, Villejuif F-94805, France

5. Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris [AP-HP], Le Kremlin Bicêtre, France

6. Department of Pathology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris [AP-HP], Le Kremlin Bicêtre, France

7. Gustave Roussy, Département de Médecine, Service de Dermatologie, Villejuif, F-94805, France

8. Gustave Roussy, Département de Médecine Oncologique, Service de pathologie thoracique, Villejuif, F-94805, France

9. Gustave Roussy, Drug Development Department [DITEP] Villejuif F-94805, France

10. Gustave Roussy Cancer Campus [GRCC], Department of Cancer Medicine, Villejuif F-94805, France

11. Micalis Institute, INRA, AgroParisTech, University Paris-Saclay, 78350 Jouy-en-Josas, France

12. University Paris-Sud, Faculté de Pharmacie, Chatenay-Malabry, Châtenay-Malabry, F-92 296, France

Funder

Institut national de la santé et de la recherche médicale

Institut National du Cancer

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/11/10/1238/20220663/jjx081.pdf

Reference40 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Pembrolizumab versus Ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

4. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

5. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-04

2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología (English Edition);2024-04

3. Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn’s disease;Clinical and Experimental Immunology;2024-03-22

4. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20

5. Targeted delivery of Fc-fused PD-L1 for effective management of acute and chronic colitis;Nature Communications;2024-02-23